Controversial effect on Erk activation of some cytotoxic drugs in human LOVO colon cancer cells

References

• Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin 2011;61:69–90
   PubMed Web of Science ®Google Scholar
• Ferlay J, Shin HR, Bray F, et al. Estimates of worldwideburden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010;127:2893–917
   PubMed Web of Science ®Google Scholar
• Saltz LB, Clarke S, Diaz-Rubio E, et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 2008;26:2013–19
   PubMed Web of Science ®Google Scholar
• Tol J, Punt JA. Monoclonal antibodies in the treatment of metastatic colorectal cancer. A review. Clin Ther 2010;32:437–53
   PubMed Web of Science ®Google Scholar
• Tol J, Koopman M, Cats A, et al. Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. N Engl J Med 2009;360:563–72
   PubMed Web of Science ®Google Scholar
• Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350:2335–42
   PubMed Web of Science ®Google Scholar
• Lièvre A, Bachet JB, Boige V, et al. KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J Clin Oncol 2008;26:374–9
   PubMed Web of Science ®Google Scholar
• Kabbinavar FF, Hambleton J, Mass RD, et al. Combined analysis of efficacy: the addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer. J Clin Oncol 2005;23:3706–12
   PubMed Web of Science ®Google Scholar
• Jacobs ET, Thompson PA, Martinez ME. Diet, gender, and colorectal neoplasia. J Clin Gastroenterol 2007;41:731–46
   PubMed Web of Science ®Google Scholar
• Lewis JS, Jordan VC. Selective estrogen receptor modulators (SERMs): mechanisms of anticarcinogenesis and drug resistance. Mutat Res 2005;591:247–63
   PubMed Web of Science ®Google Scholar
• Harris HA, Albert LM, Leathurby Y, et al. Evaluation of an estrogen receptor-beta agonist in animal models of human disease. Endocrinology 2003;144:4241–9
   PubMed Web of Science ®Google Scholar
• Katzenellenbogen JA, Katzenellenbogen BS. Nuclear hormone receptors: ligand-activated regulators of transcription and diverse cell responses. Chem Biol 1996;3:529–36
   PubMed Web of Science ®Google Scholar
• Campbell-Thompson M, Lynch IJ, Bhardwaj B. Expression of estrogen receptor (ER) subtypes and ERbeta isoforms in colon cancer. Cancer Res 2001;61:632–40
   PubMed Web of Science ®Google Scholar
• Gambacciani M, Monteleone P, Sacco A, Genazzani AR. Hormone replacement therapy and endometrial, ovarian and colorectal cancer. Best Pract Res Clin Endocrinol Metab 2003;17:139–47
   PubMed Web of Science ®Google Scholar
• Grodstein F, Martinez ME, Platz EA, et al. Postmenopausal hormone use and risk for colorectal cancer and adenoma. Ann Intern Med 1998;128:705–12
   PubMed Web of Science ®Google Scholar
• Chlebowski RT, Wactawski-Wende J, Ritenbaugh C, et al. Estrogen plus progestin and colorectal cancer in postmenopausal women. N Engl J Med 2004;350:991–1004
   PubMed Web of Science ®Google Scholar
• Calle EE, Miracle-McMahill HL, Thun MJ, Heath CW Jr. Estrogen replacement therapy and risk of fatal colon cancer in a prospective cohort of postmenopausal women. J Natl Cancer Inst 1995;87:517–23
   PubMed Web of Science ®Google Scholar
• Lai TY, Chen LC, Lin JY, et al. 17β-Estradiol inhibits prostaglandin E2-induced COX-2 expressions and cell migration by suppressing Akt and ERK1/2 signaling pathways in human LOVO colon cancer cells. Mol Cell Biochem 2010;342:63–70
   PubMed Web of Science ®Google Scholar
• Lu Z, Xu S. ERK1/2 MAP kinases in cell survival and apoptosis. IUBMB Life 2006;58:621–31
   PubMed Web of Science ®Google Scholar
• Bernstein L. Epidemiology of endocrine-related risk factors for breast cancer. J Mammary Gland Biol Neoplasia 2002;7:3–15
   PubMed Web of Science ®Google Scholar
• Chieffi P, Kisslinger A, Sinisi AA, et al. 17β-Estradiol induced activation of ERK1/2 through endogenous androgen receptor-estradiol receptor alpha-Src complex in human prostate cells. Int J Oncol 2003;23:797–801
   PubMed Web of Science ®Google Scholar
• Jordan VC. Fourteenth Gaddum Memorial Lescture. A current view of tamoxifen for the treatment and prevention of breast cancer. Br J Pharmacol 1993;110:507–17
   PubMed Web of Science ®Google Scholar
• Seay TM, Peretsman SJ, Dixon PS. Inhibition of human transitional cell carcinoma in vitro proliferation by fluoroquinolone antibiotics. J Urol 1996;155:757–62
   PubMed Web of Science ®Google Scholar
• Ebisuno S, Inagaki T, Kohjimoto Y, Ohkawa T. The cytotoxic effect of fleroxacin and ciprofloxacin on transitional cell carcinoma in vitro. Cancer 1997;80:2263–7
   PubMed Web of Science ®Google Scholar
• Aranha O, Wood Jr DP, Sarkar FH. Ciprofloxacin mediated cell growth inhibition, S/G2-M cell cycle arrest, and apoptosis in a human transitional cell carcinoma of the bladder cell line. Clin Cancer Res 2000;6:891–900
   PubMed Web of Science ®Google Scholar
• Miclau T, Edin ML, Lester GE, et al. Effect of ciprofloxacin on the proliferation of osteoblast-like MG-63 human osteosarcoma cells in vitro. J Orthop Res 1998;16:509–12
   PubMed Web of Science ®Google Scholar
• Some E, Douer D, Shaked N, Rubinstein E. In vitro effects of ciprofloxacin and pefloxacin on growth of normal human hematopoietic progenitor cells and on leukemic cell lines. J Pharmacol Exp Ther 1989;248:415–18
   PubMed Web of Science ®Google Scholar
• Chen AY, Liu LF. DNA topoisomerases: essential enzymes and lethal targets. Ann Rev Pharmacol Toxicol 1994;34:191–218
   PubMed Web of Science ®Google Scholar
• Herold C, Ocker M, Ganslmayer M, et al. Ciprofloxacin induces apoptosis and inhibits proliferation of human colorectal carcinoma cells. Br J Cancer 2002;86:443–8
   PubMed Web of Science ®Google Scholar
• Davis RJ. The mitogen-activated protein kinase signal transduction pathway. J Biol Chem 1993;268:14553–6
   PubMed Web of Science ®Google Scholar
• Xia Z, Dickens MJ, Raingeaud RJ, et al. Opposing effects of ERK and JNK-p38 MAP kinases on apoptosis. Science 1995;270:1326–31
   PubMed Web of Science ®Google Scholar
• Boulton T, Nye S, Robbins D, et al. ERKs: a family of protein-serine/threonine kinases that are activated and tyrosine phosphorylated in response to insulin and NGF. Cell 1991;65:663–75
   PubMed Web of Science ®Google Scholar
• Segal R, Greenberg M. Intracellular signalling pathways activated by neurotrophic factors. Ann Rev Neurosci 1996;19:463–89
   PubMed Web of Science ®Google Scholar
• Recchia I, Rucci N, Funari A, et al. Reduction of c-Src activity by substituted 5,7-diphenyl-pyrrolo[2,3-d]-pyrimidines induces osteoclast apoptosis in vivo and in vitro. Involvement of ERK1/2 pathway. Bone 2004;34:65–79
   PubMed Web of Science ®Google Scholar
• Lawrence JW, Darkin-Rattray S, Xie F, et al. 4-quinolones cause a selective loss of mitochondrial DNA from mouse L1210 leukemia cells. J Cell Biochem 1993;51:165–74
   PubMed Web of Science ®Google Scholar
• Jurgensmeier JM, Xie Z, Deveraux Q, et al. Bax directly induces release of cytochrome c from isolated mitochondria. Proc Natl Acad Sci USA 1998;95:4997–5002
   PubMed Web of Science ®Google Scholar
• Bratton SB, MacFarlane M, Cain K, Cohen GM. Protein complexes activate distinct caspase cascades in death receptor and stress-induced apoptosis. Exp Cell Res 2000;256:27–33
   PubMed Web of Science ®Google Scholar
• Marino M, Galluzzo P, Ascenzi P. Estrogen signaling multiple pathways to impact gene transcription. Curr Genomics 2006;7:497–508
   PubMed Web of Science ®Google Scholar
• Chang L, Karin M. Histomolecular phenotypes and outcome in adenocarcinoma of the ampulla of vater. Nature 2001;410:37–40
   PubMed Web of Science ®Google Scholar